-
Something wrong with this record ?
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
JA. Ledermann, X. Matias-Guiu, F. Amant, N. Concin, B. Davidson, C. Fotopoulou, A. González-Martin, C. Gourley, A. Leary, D. Lorusso, S. Banerjee, L. Chiva, D. Cibula, N. Colombo, S. Croce, AG. Eriksson, C. Falandry, D. Fischerova, P. Harter, F....
Language English Country England, Great Britain
Document type Practice Guideline
- MeSH
- Medical Oncology * MeSH
- Humans MeSH
- Molecular Biology MeSH
- Ovarian Neoplasms * genetics therapy MeSH
- Societies, Medical MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Practice Guideline MeSH
- Geographicals
- Spain MeSH
The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June 2022 in Valencia, Spain. The CC panel included 44 experts in the management of ovarian cancer and pathology, an ESMO scientific advisor and a methodologist. The aim was to discuss new or contentious topics and develop recommendations to improve and harmonise the management of patients with ovarian cancer. Eighteen questions were identified for discussion under four main topics: (i) pathology and molecular biology, (ii) early-stage disease and pelvic mass in pregnancy, (iii) advanced stage (including older/frail patients) and (iv) recurrent disease. The panel was divided into four working groups (WGs) to each address questions relating to one of the four topics outlined above, based on their expertise. Relevant scientific literature was reviewed in advance. Recommendations were developed by the WGs and then presented to the entire panel for further discussion and amendment before voting. This manuscript focuses on the recommendation statements that reached a consensus, their voting results and a summary of evidence supporting each recommendation.
Arbeitsgemeinschaft Gynäkologische Onkologie Study Group Germany
Cancer Science Institute National University of Singapore Singapore
Department of Biopathology Bergonié Institut Bordeaux France
Department of Gynaecology and Gynaecologic Oncology Evang Kliniken Essen Mitte Essen Germany
Department of Gynaecology and Obstetrics Cancer Center Clínica Universidad de Navarra Navarra Spain
Department of Gynecologic Oncology Istituto Europeo di Oncologia IRCCS Milan
Department of Gynecologic Oncology School of Medicine Koç University Istanbul Turkey
Department of Gynecologic Surgery Gustave Roussy Cancer Campus Villejuif France
Department of Medical Oncology Centre Léon Bérard University Claude Bernard Lyon France
Department of Medical Oncology Hospital Clínico Universitario INCLIVA CIBERONC Valencia Spain
Department of Medical Oncology Instituto Valenciano Oncologia Valencia Spain
Department of Medicine and Surgery University of Milano Bicocca Milan Italy
Department of Medicine Institut Gustave Roussy Villejuif France
Department of Medicine Yong Loo Lin School of Medicine National University of Singapore Singapore
Department of Obstetrics and Gynaecology Medical University of Innsbruck Innsbruck Austria
Department of Obstetrics and Gynecology Houston Methodist Hospital Houston USA
Department of Obstetrics and Gynecology University Hospital LMU Munich Munich
Department of Obstetrics and Gynecology University Hospital Mannheim Mannheim
Department of Oncology UCL Cancer Institute University College London London UK
Department of Pathology Belfast Health and Social Care Trust Belfast UK
Department of Pathology Norwegian Radium Hospital Oslo University Hospital Oslo
Department of Surgery and Cancer Faculty of Medicine Imperial College London London UK
Department of Woman Child and Public Health Catholic University of Sacred Heart Rome Italy
Division of Gynecologic Oncology Fondazione Policlinico Universitario A Gemelli IRCCS Rome
Hereditary Cancer Program Catalan Institute of Oncology L'Hospitalet de Llobregat Barcelona Spain
Institut Bergonié Bordeaux France
Institute of Aging Hospices Civils de Lyon Lyon
Institute of Cancer and Genomic Sciences University of Birmingham Birmingham
Institute of Clinical Medicine Faculty of Medicine University of Oslo Oslo Norway
Medical Faculty Mannheim Heidelberg University Mannheim Germany
North Eastern German Society of Gynecological Oncology Berlin
Oncology Institute of Southern Switzerland Bellinzona Switzerland
Pan Birmingham Gynaecological Cancer Centre City Hospital Birmingham UK
Sheba Medical Center Ramat Gan Israel
The Royal Marsden NHS Foundation Trust and Institute of Cancer Research London UK
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24006886
- 003
- CZ-PrNML
- 005
- 20240423155544.0
- 007
- ta
- 008
- 240412s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.annonc.2023.11.015 $2 doi
- 035 __
- $a (PubMed)38307807
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Ledermann, J A $u Department of Oncology, UCL Cancer Institute, University College London, London, UK. Electronic address: clinicalguidelines@esmo.org
- 245 10
- $a ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease / $c JA. Ledermann, X. Matias-Guiu, F. Amant, N. Concin, B. Davidson, C. Fotopoulou, A. González-Martin, C. Gourley, A. Leary, D. Lorusso, S. Banerjee, L. Chiva, D. Cibula, N. Colombo, S. Croce, AG. Eriksson, C. Falandry, D. Fischerova, P. Harter, F. Joly, C. Lazaro, C. Lok, S. Mahner, F. Marmé, C. Marth, WG. McCluggage, IA. McNeish, P. Morice, S. Nicum, A. Oaknin, JA. Pérez-Fidalgo, S. Pignata, PT. Ramirez, I. Ray-Coquard, I. Romero, G. Scambia, J. Sehouli, R. Shapira-Frommer, S. Sundar, DSP. Tan, C. Taskiran, WJ. van Driel, I. Vergote, F. Planchamp, C. Sessa, A. Fagotti
- 520 9_
- $a The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June 2022 in Valencia, Spain. The CC panel included 44 experts in the management of ovarian cancer and pathology, an ESMO scientific advisor and a methodologist. The aim was to discuss new or contentious topics and develop recommendations to improve and harmonise the management of patients with ovarian cancer. Eighteen questions were identified for discussion under four main topics: (i) pathology and molecular biology, (ii) early-stage disease and pelvic mass in pregnancy, (iii) advanced stage (including older/frail patients) and (iv) recurrent disease. The panel was divided into four working groups (WGs) to each address questions relating to one of the four topics outlined above, based on their expertise. Relevant scientific literature was reviewed in advance. Recommendations were developed by the WGs and then presented to the entire panel for further discussion and amendment before voting. This manuscript focuses on the recommendation statements that reached a consensus, their voting results and a summary of evidence supporting each recommendation.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a lékařská onkologie $7 D008495
- 650 _2
- $a společnosti lékařské $7 D012955
- 650 12
- $a nádory vaječníků $x genetika $x terapie $7 D010051
- 650 _2
- $a molekulární biologie $7 D008967
- 651 _2
- $a Španělsko $7 D013030
- 655 _2
- $a směrnice pro lékařskou praxi $7 D017065
- 700 1_
- $a Matias-Guiu, X $u CIBERONC, Madrid; Department of Pathology, Hospital Universitari Arnau de Vilanova, IRBLLEIDA, University of Lleida, Lleida; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, University of Barcelona, Barcelona, Spain. Electronic address: admin@esp-pathology.org
- 700 1_
- $a Amant, F $u Department of Gynaecologic Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium; Department of Gynecology, Center for Gynecological Oncology Amsterdam, Netherlands Cancer Institute, Amsterdam, The Netherlands
- 700 1_
- $a Concin, N $u Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Innsbruck, Austria; Department of Gynaecology and Gynaecologic Oncology, Evang. Kliniken Essen-Mitte, Essen, Germany
- 700 1_
- $a Davidson, B $u Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
- 700 1_
- $a Fotopoulou, C $u Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK
- 700 1_
- $a González-Martin, A $u Department of Medical Oncology and Program in Solid Tumours-Cima, Cancer Center Clínica Universidad de Navarra, Madrid, Spain
- 700 1_
- $a Gourley, C $u Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK
- 700 1_
- $a Leary, A $u Department of Medicine, Institut Gustave Roussy, Villejuif, France
- 700 1_
- $a Lorusso, D $u Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; Department of Woman, Child and Public Health, Catholic University of Sacred Heart, Rome, Italy
- 700 1_
- $a Banerjee, S $u The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK
- 700 1_
- $a Chiva, L $u Department of Gynaecology and Obstetrics, Cancer Center Clínica Universidad de Navarra, Navarra, Spain
- 700 1_
- $a Cibula, D $u Department of Gynecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Colombo, N $u Department of Gynecologic Oncology, Istituto Europeo di Oncologia IRCCS, Milan; Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
- 700 1_
- $a Croce, S $u Department of Biopathology, Bergonié Institut, Bordeaux, France
- 700 1_
- $a Eriksson, A G $u Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Department of Gynecologic Oncology, Division of Cancer Medicine, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
- 700 1_
- $a Falandry, C $u Institute of Aging, Hospices Civils de Lyon, Lyon; CarMeN Laboratory, INSERM U1060/Université Lyon 1/INRAE U1397/Hospices Civils Lyon, Pierre-Bénite, France
- 700 1_
- $a Fischerova, D $u Department of Gynecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Harter, P $u Department of Gynaecology and Gynaecologic Oncology, Evang. Kliniken Essen-Mitte, Essen, Germany; Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group, Germany
- 700 1_
- $a Joly, F $u GINECO Group, Department of Medical Oncology, Centre François-Baclesse, University of Caen Normandy, Caen, France
- 700 1_
- $a Lazaro, C $u Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL-CIBERONC), L'Hospitalet de Llobregat, Barcelona, Spain
- 700 1_
- $a Lok, C $u Department of Gynecology, Center for Gynecological Oncology Amsterdam, Netherlands Cancer Institute, Amsterdam, The Netherlands
- 700 1_
- $a Mahner, S $u Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group, Germany; Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich
- 700 1_
- $a Marmé, F $u Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group, Germany; Department of Obstetrics and Gynecology, University Hospital Mannheim, Mannheim; Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
- 700 1_
- $a Marth, C $u Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Innsbruck, Austria
- 700 1_
- $a McCluggage, W G $u Department of Pathology, Belfast Health and Social Care Trust, Belfast, UK
- 700 1_
- $a McNeish, I A $u Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK
- 700 1_
- $a Morice, P $u Department of Gynecologic Surgery, Gustave Roussy Cancer Campus, Villejuif, France
- 700 1_
- $a Nicum, S $u Department of Oncology, UCL Cancer Institute, University College London, London, UK
- 700 1_
- $a Oaknin, A $u Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona
- 700 1_
- $a Pérez-Fidalgo, J A $u Department of Medical Oncology, Hospital Clínico Universitario - INCLIVA, CIBERONC, Valencia, Spain
- 700 1_
- $a Pignata, S $u Department of Urology and Gynecology, Istituto Nazionale Tumori di Napoli, IRCCS Fondazione Pascale, Napoli, Italy
- 700 1_
- $a Ramirez, P T $u Department of Obstetrics and Gynecology, Houston Methodist Hospital, Houston, USA
- 700 1_
- $a Ray-Coquard, I $u Department of Medical Oncology, Centre Léon Bérard, University Claude Bernard, Lyon, France
- 700 1_
- $a Romero, I $u Department of Medical Oncology, Instituto Valenciano Oncologia, Valencia, Spain
- 700 1_
- $a Scambia, G $u Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; Department of Woman, Child and Public Health, Catholic University of Sacred Heart, Rome, Italy
- 700 1_
- $a Sehouli, J $u North-Eastern German Society of Gynecological Oncology (NOGGO), Berlin; Department of Gynecology with Center for Oncological Surgery, Charité Berlin University of Medicine, Berlin, Germany
- 700 1_
- $a Shapira-Frommer, R $u Sheba Medical Center, Ramat Gan, Israel
- 700 1_
- $a Sundar, S $u Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham; Pan Birmingham Gynaecological Cancer Centre, City Hospital, Birmingham, UK
- 700 1_
- $a Tan, D S P $u Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; National University of Singapore (NUS) Centre for Cancer Research, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Cancer Science Institute, National University of Singapore, Singapore; Department of Haematology-Oncology, National University Cancer Institute Singapore, National University Hospital, Singapore, Singapore
- 700 1_
- $a Taskiran, C $u Department of Gynecologic Oncology, School of Medicine, Koç University, Istanbul, Turkey
- 700 1_
- $a van Driel, W J $u Department of Gynecology, Center for Gynecological Oncology Amsterdam, Netherlands Cancer Institute, Amsterdam, The Netherlands
- 700 1_
- $a Vergote, I $u Department of Gynaecologic Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium
- 700 1_
- $a Planchamp, F $u Institut Bergonié, Bordeaux, France
- 700 1_
- $a Sessa, C $u Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
- 700 1_
- $a Fagotti, A $u Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; Department of Woman, Child and Public Health, Catholic University of Sacred Heart, Rome, Italy. Electronic address: guidelines@esgo.org
- 773 0_
- $w MED00000432 $t Annals of oncology $x 1569-8041 $g Roč. 35, č. 3 (2024), s. 248-266
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38307807 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423155540 $b ABA008
- 999 __
- $a ok $b bmc $g 2081077 $s 1216653
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 35 $c 3 $d 248-266 $e 20240201 $i 1569-8041 $m Annals of oncology $n Ann Oncol $x MED00000432
- LZP __
- $a Pubmed-20240412
